- CONTACT-03 evaluated cabozantinib plus atezolizumab versus cabozantinib for locally advanced or metastatic clear cell or non-clear cell (papillary or unclassified only) renal cell carcinoma (RCC) who progressed during or after immune checkpoint inhibitor therapy (either combination or monotherapy).
- The safety profile of the combination of cabozantinib and atezolizumab observed in the trial was consistent with the known safety profiles for each single agent, and no new safety signals were identified with the combination.
Exelixis’ Phase 3 CONTACT-03 Study Did Not Meet Its Primary Endpoint Of Progression-Free Survival; Shares Fall
CONTACT-03 evaluated cabozantinib plus atezolizumab versus cabozantinib for locally advanced or metastatic clear cell or non-clear cell (papillary or unclassified only) renal cell carcinoma (RCC) who progressed during
